Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals, Inc. (NASDAQ: ACMN) is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting amyloid-beta oligomers for the treatment of Alzheimer's disease. The company's website is investors.acumenpharm.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Acumen Pharmaceuticals, Inc. does
In the company’s own words
Acumen Pharmaceuticals, Inc. (NASDAQ: ACMN) is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting amyloid-beta oligomers for the treatment of Alzheimer's disease. The company's website is investors.acumenpharm.com.
Acumen's primary focus is advancing sabirnetug, a humanized monoclonal antibody designed to selectively target soluble amyloid-beta oligomers, which the company believes represent a key underlying cause of Alzheimer's disease pathology. Sabirnetug demonstrates approximately 8,750-fold greater selectivity for amyloid-beta oligomers compared to monomeric amyloid-beta and limited binding to amyloid plaques, differentiating it from existing anti-amyloid therapies. The company completed a Phase 1 clinical trial called INTERCEPT-AD in 2023, which established proof of mechanism in early Alzheimer's disease patients and demonstrated favorable safety and target engagement. Acumen is currently conducting ALTITUDE-AD, a Phase 2 randomized, double-blind, placebo-controlled trial with 542 participants, with top-line results expected in late 2026.
Beyond sabirnetug, Acumen is developing blood-brain barrier-penetrating amyloid-beta oligomer-targeted therapies through a collaboration with JCR Pharmaceuticals Co. Ltd., announced in July 2025. The company also partnered with Halozyme, Inc. in November 2023 to develop a subcutaneous formulation of sabirnetug, with Phase 1 results announced in March 2025 demonstrating feasibility of this alternative administration route.
The company's scientific approach is based on decades of research into soluble amyloid-beta oligomers as primary neurotoxins in Alzheimer's disease, pioneered by the company's scientific founders. Sabirnetug was developed through over a decade of research, including a prior drug discovery partnership with Merck & Co. from 2003 to 2011. The FDA granted Fast Track designation to sabirnetug in October 2022, recognizing the potential importance of this therapeutic approach.
Acumen does not operate manufacturing facilities and relies on contract manufacturing organizations for sabirnetug production. The company targets early Alzheimer's disease patients, including those with mild cognitive impairment or mild dementia who are amyloid-positive, representing an estimated four to five million people in the United States.
Company details
- Sector
- Healthcare
- Industry
- Biological Products
- Headquarters
- NEWTON, MA
- Fiscal year end
- December
- CIK
- 1576885
- SIC
- 2836
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Acumen Pharmaceuticals, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Acumen Pharmaceuticals, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Acumen Pharmaceuticals, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Acumen Pharmaceuticals, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Acumen Pharmaceuticals, Inc.'s last four quarterly filings that the numbers alone won't show?”